Results 161 to 170 of about 3,471,294 (187)

P-1530. Evaluation of Phenotypic Cross-Resistance between Cefiderocol and β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US Medical Centers

Sean Nguyen, Boudewijn L DeJonge, Jason J Bryowsky, Joshua Maher, Rodrigo E. Mendes, Miki Takemura, Yoshinori Yamano   +6 more
openalex   +1 more source

Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa

Stephanie L Egge, Donghoon Kang, Nazanin Pouya, Philip C Thornton, Erika Flores, Karim Clarke, Max W Adelman, Cornelius Rosenbaum, Rodrigo Baptista, Cesar A Arias, Vincent H. Tam, Michael J Satlin, William R Miller   +12 more
openalex   +1 more source

In vivo emergence of cross-resistance to ceftazidime/avibactam and cefiderocol through selection of KPC variants in Klebsiella pneumoniae clinical isolates

Gabriele Bianco, Jacqueline Findlay, Sara Comini, Cristina Costa, Patrice Nordmann, Matteo Boattini   +5 more
openalex   +1 more source

IS903B-mediated cirA Inactivation Confers Cefiderocol Resistance and Adaptive Fitness in Carbapenem-resistant Klebsiella Pneumoniae

Yuxuan Liu, Xinyue Dai, Hanxu Hong, Chuwen Zhao, Cao Yun, Linping Fan, Yang Liu   +6 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: A warning from multicenter clinical data in China

Journal of Infection
AIMS This study aimed to evaluate the in vitro efficacy of cefiderocol and other agents against carbapenem-resistant Escherichia coli (CREC) clinical isolates in China and to elucidate the genetic mechanisms underlying cefiderocol resistance. METHODS A
Junxin Zhou, Qianyi Chen, Ying Cui
exaly   +2 more sources

CefiderocolFinder: a tool for detecting genetic adaptations implicated in cefiderocol resistance.

Clinical Microbiology and Infection
OBJECTIVES Cefiderocol is a novel last-resort cephalosporin antimicrobial increasingly used for difficult-to-treat infections by multidrug-resistant microorganisms (MDRO), and is effective against carbapenem-resistant Enterobacterales and Pseudomonas ...
Bryan van den Brand, D. Notermans, N. Verkaik, S. Lansu, John W. A. Rossen, A. Hendrickx, A. V. van Arkel, M. Leversteijn-van Hall, W. van den Bijllaardt, R. van Mansfeld, K. van Dijk, B. Zwart, B. Diederen, H. Berkhout, A. Ott, K. Waar, W. Ang, J. da Silva, A. Vlek, J. Stohr, L. Bode, A. Jansz, S. Paltansing, A. J. van Griethuysen, J. R. Lo Ten Foe, M. van Trijp, M. Wong, A. Muller, M. V. D. van der Linden, M. van Rijn, S. Debast, E. Kolwijck, N. Al Naiemi, T. Schulin, S. Dinant, S. V. van Mens, D. C. Melles, J. Stuart, P. Gruteke, A. V. van Dam, J. Rahamat-Langendoen, B. Maraha, J. Sinnige, E. van der Vorm, M. V. van Meer, M. de Graaf, E. de Jong, S. Vainio, E. Heikens, M. Reijer, J. Dorigo-Zetsma, A. Troelstra, E. Bathoorn, J. de Vries, D. V. van Dam, E. de Brauwer, R. Steingrover, C. Oliveira dos Santos   +57 more
semanticscholar   +5 more sources

Rapid cefiderocol NP test for detection of cefiderocol susceptibility/resistance in Enterobacterales

Journal of Antimicrobial Chemotherapy, 2022
Abstract Background Cefiderocol is among the latest generation of commercialized antibiotics against a large variety of MDR Gram-negative bacteria including carbapenem-resistant Enterobacterales and non-fermenters such as Pseudomonas aeruginosa and Acinetobacter baumannii.
Patrice Nordmann, Maxime Bouvier, Laurent Poirel, Mustafa Sadek   +3 more
openaire   +2 more sources

Cefiderocol: Clinical application and emergence of resistance

Drug Resistance Updates
Antibacterial drug resistance of gram-negative bacteria (GNB) results in high morbidity and mortality of GNB infection, seriously threaten human health globally. Developing new antibiotics has become the critical need for dealing with drug-resistant bacterial infections.
Hong Du
exaly   +3 more sources

NDM-driven cefiderocol resistance: effect and therapeutic considerations.

The Lancet Infectious Diseases
Brenda A Warecki, P. Tamma, R. Bonomo, Alejandro J. Vila   +3 more
semanticscholar   +3 more sources